Bepotastine besilate ophthalmic solution 1.5% for alleviating nasal symptoms in patients with allergic conjunctivitis.

about

Bepotastine besilate ophthalmic solution 1.5% for alleviating nasal symptoms in patients with allergic conjunctivitis.

Item

http://www.wikidata.org/entity/Q55365208

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Bepotastine besilate ophthalmi ...... with allergic conjunctivitis.

@en

Bepotastine besilate ophthalmi ...... with allergic conjunctivitis.

@nl

type

Item

label

Bepotastine besilate ophthalmi ...... with allergic conjunctivitis.

@en

Bepotastine besilate ophthalmi ...... with allergic conjunctivitis.

@nl

prefLabel

Bepotastine besilate ophthalmi ...... with allergic conjunctivitis.

@en

Bepotastine besilate ophthalmi ...... with allergic conjunctivitis.

@nl

P1476

Bepotastine besilate ophthalmi ...... with allergic conjunctivitis.

@en

P2093

Jon I Williams

http://www.w3.org/2001/XMLSchema#string

Megan E Cavet

http://www.w3.org/2001/XMLSchema#string

Paul J Gomes

http://www.w3.org/2001/XMLSchema#string

Warner W Carr

http://www.w3.org/2001/XMLSchema#string

P2860

The diagnosis and management of rhinitis: an updated practice parameter

Comparison of the conjunctival allergen challenge model with the environmental model of allergic conjunctivitis.

Treatment of allergic conjunctivitis with bepotastine besilate ophthalmic solution 1.5%.

The epidemiology of ocular and nasal allergy in the United States, 1988-1994.

Dose-dependent protection by azelastine eye drops against pollen-induced allergic conjunctivitis. A double-blind, placebo-controlled study.

Intranasal corticosteroids versus topical H1 receptor antagonists for the treatment of allergic rhinitis: a systematic review with meta-analysis.

Conjunctival allergen challenge: models in the investigation of ocular allergy.

The Allergic Rhinitis - Clinical Investigator Collaborative (AR-CIC): nasal allergen challenge protocol optimization for studying AR pathophysiology and evaluating novel therapies

Efficacy and safety of olopatadine hydrochloride 0.77% in patients with allergic conjunctivitis using a conjunctival allergen-challenge model

Comparative efficacy of bepotastine besilate 1.5% ophthalmic solution versus olopatadine hydrochloride 0.2% ophthalmic solution evaluated by patient preference

P304

29-39

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/JAA.S160687

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-03-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29615844

http://www.w3.org/2001/XMLSchema#string

P932

5870655

http://www.w3.org/2001/XMLSchema#string